Anticancer drug development: Moving away from the old habits

Current Opinion in Oncology

Volumn 26, Issue 3, 2014, Pages 334-339

  Ades, Felipe ^a   Zardavas, Dimitrios ^a,b   Aftimos, Philippe ^a   Awada, Ahmad ^a  

^a Medical Oncology Clinic   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARRY 438162; AZD 4547; BUPARLISIB; BYL 719; CISPLATIN; CYTOTOXIC AGENT; ERLOTINIB; GEFITINIB; ICOTINIB; P 1446A 05; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL KILLING; DOSE RESPONSE; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; LUNG CANCER; MAXIMUM TOLERATED DOSE; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84899492361     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000076     Document Type: Review

References (26)

1. Reminick G. Nightmare in Bari: the World War II Liberty ship poison gas disaster and coverup. Palo Alto, California: Glencannon Press; 2001.
2. Goodman LS, Gilman A, Brunton LL. Goodman & Gilman's manual of pharmacology and therapeutics. 12th ed. New York: McGraw-Hill Medical; 2008.
3. National Cancer Act of 1971-OGCR. http://legislative.cancer.gov/history/ phsa/1971. [Accessed 13 November 2012].
4. Grein A. Antitumor anthracyclines produced by Streptomyces peucetius. Adv Appl Microbiol 1987; 32:203-214.
5. Adams JD, Flora KP, Goldspiel BR, et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monographs 1993; 141-147.
6. Himes RH. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991; 51:257-267.
7. Torck M, Pinkas M. Camptothecin and derivatives: a new class of antitumor agents. J Pharm Belg 1996; 51:200-207.
8. Vincenzi B, Napolitano A, Frezza AM, et al. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics 2010; 11:865-878. doi: 10.2217/pgs.10.69.
9. Wilcox WS, Schabel FM, Skipper HE. Experimental Evaluation of Potential Anticancer Agents XV. On the relative rates of growth and host kill of 'single' leukemia cells that survive in vivo cytoxan therapy. Cancer Res 1966; 26:1009-1014.
10. Pao W, Girard N. New driver mutations in nonsmall-cell lung cancer. Lancet Oncol 2011; 12:175-180. doi:10.1016/S1470-2045(10)70087-5.
11. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752. doi:10.1038/35021093.
12. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1:44-53. doi:10.1158/2159-8274.CD- 10-0010.
13. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86:97-100. doi:10.1038/clpt.2009.68.
14. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383. doi:10.1158/1078-0432.CCR-12-1627.
15. Gebhart G, Gámez C, Holmes E, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 2013; 54:1862-1868.
16. Kraeber-Bodé ré F, Carlier T, Naegelen VM, et al. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med 2012; 53:1836-1846. doi:10.2967/jnumed.112.109421.
17. Hendlisz A, Golfinopoulos V, Deleporte A, et al. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer 2013; 13:190. doi:10.1186/1471-2407-13-190.
18. Awada A, Rodriguez AA, Kong A, et al. The ENCHANT-1 trial (NCT01677455): an open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC). J Clin Oncol 2013; 31 (suppl):abstr TPS1136; http://meetinglibrary.asco.org/content/117684-132. [Accessed 22 November 2013]
19. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22:701-706. doi:10.1038/nbt968.
20. Yeh HH,Ogawa K, Balatoni J, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci USA 2011; 108:1603-1608. doi:10.1073/pnas.1010744108.
21. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011; 108:9578-9582. doi:10.1073/pnas. 1106383108.
22. Gomez-Roca CA, Lacroix L, Massard C, et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol 2012; 23:1301-1306. doi:10.1093/annonc/mdr383.
23. Lee J, Hays JL, Noonan AM, et al. Feasibility and safety of sequential researchrelated tumor core biopsies in clinical trials. Cancer 2013; 119:1357-1364. doi:10.1002/cncr.27916.
24. Balko JM, Cook RS, Vaught DB, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012; 18:1052-1059. doi:10.1038/nm. 2795.
25. Murtaza M, Dawson S-J, Tsui DWY, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112. doi:10.1038/nature12065.
26. Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209. doi:10.1056/NEJMoa1213261.